Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache

Chronic Migraine Clinical Trial

— RZN  

Official title:

Human CT: Efficacy & Safety of MIGRA-ZEN RELIEF PLUS:Herbal Supp:Extracts Juniper Willow Goldenrod Dandelion Meadowsweet Whole Grape In Rx of Chronic Migraine Headache. Randomized, Double-Blind, Placebo Cont. Study P.II (PoC Study)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01135784
• Other study ID #: RZN 1
• Status: Not yet recruiting
• Phase: Phase 2
• First received: May 26, 2010
• Last updated: June 13, 2011
• Start date: October 2011
• Est. completion date: July 2012

Study information

• Verified date: March 2011
• Source: RZN Nutraceuticals, Inc.
• Contact: Mark Lubin, MD
• Phone: 305-971-3541
• Email: mark[@]rznnutra.com
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to study MIGRA-ZEN RELIEF PLUS, an all-natural herbal dietary supplement product, with respect to alleviating and/or stopping migraine headache pain compared to a placebo when used prophylactically. This study will involve subjects suffering from chronic migraine headaches.

Description:

The purpose of this 90-day, randomized, double-blind, placebo controlled study is to evaluate the efficacy of an all-natural herbal dietary supplement product, (Investigational Product, or IP), with respect to alleviating and/or stopping migraine headache pain compared to a placebo when used prophylactically every day, and to evaluate the safety/risk of its use by observing the absence/presence of adverse event (AE/SAE) reports and the normalcy of blood work, urinalysis, and liver enzyme tests. The primary end-point is the time-course and depth of the frequency reduction of migraine attacks. The secondary end-points will be the absence/presence of detectable adverse liver function and urinalysis test results as well as the dearth/abundance of AE/SAE reports that may indicate patient safety/risk when using the IP.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: July 2012
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female subjects 18 years of age or older.

• Prior to this study subject must have been diagnosed with migraines according to IHS criteria by a qualified healthcare professional with some experience in the diagnosis of migraines and have suffered with them for one year prior to the start of the study.

• Migraine symptoms/attacks must have presented for a minimum of the last consecutive three (3) months at a minimum average frequency of six (6) times per month and must have been severe-extreme (grade 7-10) on a linear scale of 0-10, where 0=no pain and 10=unbearable maximum pain.

• Subjects who are able to follow the protocol as designed by RZN Nutraceuticals, Inc. and Teva Pharmaceutical Industries.

• Generally good health

Exclusion Criteria:

• Subjects currently taking any prophylactic treatment for migraine headaches

• History of head trauma or brain cancer.

• Candidate subjects with any medical condition that, in the opinion of the investigators or intake staff, would jeopardize the safety of the patient, affect the validity of the data collected from the subject, or would challenge the subject's ability to complete the study protocol for 90 days.

• Known renal insufficiency or kidney disease of any grade

• Any illness causing severe coughing so as to avoid introducing "coughing migraine" per IHS classification 4.2, G44.803.

• History of drug addiction.

• Females of child-bearing potential who do not practice medically acceptable methods of contraception surgical, sterilization, intrauterine device (IUD), hormonal preparations or double barrier method (e.g. condom or diaphragm and spermicide)

• Subjects with uncontrolled hypertension (e.g. BP>150/100).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Chronic Migraine
• Migraine Disorders

Intervention

Dietary Supplement:
• MIGRA-ZEN RELIEF PLUS
one 2-capsule dose per 24hrs for a total of 180 caps over 90 days
• Placebo for Migrazen relief plus
2 capsule dose per 24 hours for 90 days

Locations

Country	Name	City	State
Israel	Rabin Medical Centre	Petach Tikva
Israel	Sourasky Medical Centre	Tel Aviv

Sponsors (1)

Lead Sponsor	Collaborator
RZN Nutraceuticals, Inc.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The reduction of migraine attacks	The time-course and depth of the frequency in the reduction of migraine attacks	90 Days	Yes
Secondary	AEs SAEs	The secondary end-points will be the absence/presence of detectable adverse liver function and urinalysis test results as well as the dearth/abundance of AE/SAE reports that may indicate patient safety/risk when using the IP.	90 days	Yes